StreetInsider.com News Articles

Form S-3 Bluejay Diagnostics,

Wed, 17 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260617/26660971.html

Form S-3 Bluejay Diagnostics,

Wed, 17 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260617/26660971.html

Form 8-K Bluejay Diagnostics, For: Jun 09

Tue, 09 Jun 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260609/26624871.html

Form 8-K Bluejay Diagnostics, For: Jun 09

Tue, 09 Jun 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260609/26624871.html

Form 8-K Bluejay Diagnostics, For: Jun 02

Mon, 08 Jun 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260608/26618357.html

Form 8-K Bluejay Diagnostics, For: Jun 02

Mon, 08 Jun 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260608/26618357.html

Bluejay Diagnostics closes $8.5 million private placement

Fri, 05 Jun 2026 20:13:38 -0400

Bluejay Diagnostics Inc. (NASDAQ: BJDX) closed a private placement that raised $8.5 million in gross proceeds, with the potential for an additional $15.2 million if warrants are fully exercised.

The medical diagnostics company sold 3,655,917 shares of common stock and accompanying warrants at $2.325 per share. The offering included series G warrants and short-term series H warrants, both with an exercise price of $2.075 per share and immediately exercisable upon issuance.

The series G warrants expire five years from the effective date of the resale registration statement, while the short-term series H warrants expire 24 months from that date. H.C. Wainwright &

Bluejay Diagnostics closes $8.5 million private placement

Fri, 05 Jun 2026 20:13:38 -0400

Bluejay Diagnostics Inc. (NASDAQ: BJDX) closed a private placement that raised $8.5 million in gross proceeds, with the potential for an additional $15.2 million if warrants are fully exercised.

The series G warrants expire five years from the effective date of the resale registration statement, while the short-term series H warrants expire 24 months from that date. H.C. Wainwright &

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Fri, 05 Jun 2026 20:13:00 -0400

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash, it is anticipated that the cash runway would extend well beyond FDA approval and first full year of commercialization

ACTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on near-patient testing for critical care, today

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Fri, 05 Jun 2026 20:13:00 -0400

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Fri, 05 Jun 2026 20:13:00 -0400

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Fri, 05 Jun 2026 20:13:00 -0400

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

Form SCHEDULE 13G Bluejay Diagnostics, Filed by: INTRACOASTAL CAPITAL, LLC

Fri, 05 Jun 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260605/26612312.html

Form SCHEDULE 13G Bluejay Diagnostics, Filed by: INTRACOASTAL CAPITAL, LLC

Fri, 05 Jun 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260605/26612312.html

Form SCHEDULE 13D/A Bluejay Diagnostics, Filed by: NORTHSTRIVE FUND II LP

Tue, 02 Jun 2026 21:01:00 -0400

si-local-file:///var/storage/secattach/20260602/26594064.html

Form SCHEDULE 13D/A Bluejay Diagnostics, Filed by: NORTHSTRIVE FUND II LP

Tue, 02 Jun 2026 21:01:00 -0400

si-local-file:///var/storage/secattach/20260602/26594064.html

Form SCHEDULE 13D/A Bluejay Diagnostics, Filed by: Braeden Lichti

Tue, 02 Jun 2026 20:11:00 -0400

si-local-file:///var/storage/secattach/20260602/26593963.html

Form SCHEDULE 13D/A Bluejay Diagnostics, Filed by: Braeden Lichti

Tue, 02 Jun 2026 20:11:00 -0400

si-local-file:///var/storage/secattach/20260602/26593963.html

Bluejay Diagnostics raises $8.5 million in private placement

Tue, 02 Jun 2026 12:19:16 -0400

Bluejay Diagnostics Inc. (NASDAQ: BJDX) announced it has entered into definitive agreements for a private placement expected to generate $8.5 million in gross proceeds, with potential additional proceeds of up to $15.1 million if warrants are fully exercised.

The medical diagnostics company will sell 3,655,917 shares of common stock and accompanying warrants at $2.325 per share. The offering includes series G warrants and short-term series H warrants, both with an exercise price of $2.075 per share and immediate exercisability upon issuance.

The series G warrants will expire five years from the effective date of the resale registration statement, while the short-term series

Bluejay Diagnostics raises $8.5 million in private placement

Tue, 02 Jun 2026 12:19:16 -0400

The series G warrants will expire five years from the effective date of the resale registration statement, while the short-term series

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 02 Jun 2026 12:19:00 -0400

$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants

ACTON, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on near-patient testing for critical care, today

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 02 Jun 2026 12:19:00 -0400

$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 02 Jun 2026 12:19:00 -0400

$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 02 Jun 2026 12:19:00 -0400

$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants

Form 8-K Bluejay Diagnostics, For: May 27

Tue, 02 Jun 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260602/26586984.html